Sukhraj Pal Singh Dhami

Sukhraj Pal Singh Dhami

Auto-generated profile, based on publicly available information

Sukhraj Pal Singh Dhami

Apoptosis Research Centre, School of Natural Sciences, National University of Ireland Galway, Galway, Ireland

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 June 2020 in Journal of Thrombosis and Haemostasis
Verified
Journal Article
Closed access
PDF file
SPSean Patmore
Sean Patmore
SDSukhraj Pal S. Dhami
Sukhraj Pal S. Dhami
JOJamie M. O'SUllivan
Jamie M. O'SUllivan

10 July 2022 in Journal of Thrombosis and Haemostasis
Verified
Journal Article
Open access
SDSukhraj Pal Singh Dhami
Sukhraj Pal Singh Dhami
SPSean Patmore
Sean Patmore
CCClaire Comerford
Claire Comerford
CBCiara M. Byrne
Ciara M. Byrne
BCBrenton Cavanagh
Brenton Cavanagh
JOJamie M. O'SUllivan
Jamie M. O'SUllivan
Breast cancer results in a three‐ to four‐fold increased risk of venous thromboembolism (VTE), which is associated with reduced patient survival. Despite this, the mechanisms underpinning breast cancer‐associated thrombosis remain poorly defined. Tumor cells can trigger endothelial cell (EC) activation resulting in increased von Willebrand factor (VWF) secretion. Importantly, elevated plasma VWF levels constitute an independent biomarker for VTE risk. Moreover, in a model of melanoma, treatment with low molecular weight heparin (LMWH) negatively regulated VWF secretion and attenuated tumor metastasis. To investigate the role of VWF in breast cancer metastasis and examine the effect of LMWH in modulating EC activation and breast tumor transmigration. von Willebrand factor levels were measured by ELISA. Primary ECs were used to assess tumor‐induced activation, angiogenesis, tumor adhesion, and transendothelial migration. Patients with metastatic breast cancer have markedly elevated plasma VWF:Ag levels that also correlate with poorer survival. MDA‐MB‐231 and MCF‐7 breast cancer cells induce secretion of VWF, angiopoietin‐2, and osteoprotegerin from ECs, which is further enhanced by the presence of platelets. Vascular endothelial growth factor‐A (VEGF‐A) plays an important role in modulating breast cancer‐induced VWF release. Moreover, VEGF‐A from breast tumor cells also contributes to a pro‐angiogenic effect on ECs. VWF multimers secreted from ECs, in response to tumor‐VEGF‐A, mediate adhesion of breast tumor cells along the endothelium. LMWH inhibits VWF‐breast tumor adhesion and transendothelial migration. Our findings highlight the significant crosstalk between tumor cells and the endothelium including increased VWF secretion which may contribute to tumor metastasis.

8 June 2015 in Oncogene
Verified
Journal Article
Closed access
PDF file
LOL O'LEary
L O'LEary
ASA M van der Sloot
A M van der Sloot
CRC R Reis
C R Reis
SDS Deegan
S Deegan
ARAideen Ryan
Aideen Ryan
ESEva Szegezdi
Eva Szegezdi

25 October 2018 in Scientific Reports
Verified
Journal Article
Open access
PDF file
EREimear O’ Reilly
Eimear O’ Reilly
SDSukhraj Pal S. Dhami
Sukhraj Pal S. Dhami
DBDenis V. Baev
Denis V. Baev
COCsaba Ortutay
Csaba Ortutay
AHAnna Halpin-McCormick
Anna Halpin-McCormick
ESEva Szegezdi
Eva Szegezdi
Acute myeloid leukaemia (AML) is an aggressive cancer with 50–75% of patients relapsing even after successful chemotherapy. The role of the bone marrow microenvironment (BMM) in protecting AML cells from chemotherapeutics and causing consequent relapse is increasingly recognised. However the role that the anti-apoptotic Bcl-2 proteins play as effectors of BMM-mediated drug resistance are less understood. Here we show that bone marrow mesenchymal stromal cells (BMSC) provide resistance to AML cells against BH3-mimetics, cytarabine and daunorubicin, but this is not mediated by Bcl-2 and/or Bcl-XL as previously thought. Instead, BMSCs induced Mcl-1 expression over Bcl-2 and/or Bcl-XL in AML cells and inhibition of Mcl-1 with a small-molecule inhibitor, A1210477, or repressing its expression with the CDC7/CDK9 dual-inhibitor, PHA-767491 restored sensitivity to BH3-mimetics. Furthermore, combined inhibition of Bcl-2/Bcl-XL and Mcl-1 could revert BMSC-mediated resistance against cytarabine + daunorubicin. Importantly, the CD34+/CD38− leukemic stem cell-encompassing population was equally sensitive to the combination of PHA-767491 and ABT-737. These results indicate that Bcl-2/Bcl-XL and Mcl-1 act in a redundant fashion as effectors of BMM-mediated AML drug resistance and highlight the potential of Mcl-1-repression to revert BMM-mediated drug resistance in the leukemic stem cell population, thus, prevent disease relapse and ultimately improve patient survival.

1 September 2016 in Drug Discovery Today
Verified
Journal Article
Closed access
SDSukhraj Pal S. Dhami
Sukhraj Pal S. Dhami
SKShanthi S. Kappala
Shanthi S. Kappala
ATAlexander Thompson
Alexander Thompson
ESEva Szegezdi
Eva Szegezdi

28 April 2020 in British Journal of Haematology
Verified
Journal Article
Open access
PDF file
SDSukhraj Pal S. Dhami
Sukhraj Pal S. Dhami
ATAndrea Tirincsi
Andrea Tirincsi
DBDenis Baev
Denis Baev
JKJanusz Krawczyk
Janusz Krawczyk
JQJohn Quinn
John Quinn
ESEva Szegezdi
Eva Szegezdi
The British Journal of Haematology publishes original research papers in clinical, laboratory and experimental haematology. The Journal also features annotations, reviews, short reports, images in haematology and Letters to the Editor.